Citation：
黄成铭, 李亚伦, 刘燕扬, 陈凤. 阿来替尼一线治疗晚期ALK融合阳性肺大细胞神经内分泌癌患者一例. Chinese Journal of Respiratory and Critical Care Medicine, 2024, 23(8): 583-586. doi: 10.7507/1671-6205.202401021
Copy
Copyright © the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
| 1. |
Andrini E, Marchese PV, De Biase D, et al. Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges. J Clin Med 2022, 11(5): 1461.
|
| 2. |
|
| 3. |
|
| 4. |
WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press (2015).
|
| 5. |
|
| 6. |
|
| 7. |
Rekhtman N, Pietanza C M, Sabari J, et al. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Modern Pathol , 2018, 31(1): 111-121.
|
| 8. |
Miyoshi T, Umemura S, Matsumura Y, et al. Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clin Cancer Res. 2017, 23(3): 757-765.
|
| 9. |
|
| 10. |
Hayashi N, Fujita A, Saikai T, et al. Large cell neuroendocrine carcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement with response to alectinib, Internal Med, 2018, 57(5): 713-716.
|
| 11. |
|
| 12. |
|
| 13. |
|
| 14. |
|
| 15. |
|
| 16. |
|
- 1. Andrini E, Marchese PV, De Biase D, et al. Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges. J Clin Med 2022, 11(5): 1461.
- 2.
- 3.
- 4. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press (2015).
- 5.
- 6.
- 7. Rekhtman N, Pietanza C M, Sabari J, et al. Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Modern Pathol , 2018, 31(1): 111-121.
- 8. Miyoshi T, Umemura S, Matsumura Y, et al. Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clin Cancer Res. 2017, 23(3): 757-765.
- 9.
- 10. Hayashi N, Fujita A, Saikai T, et al. Large cell neuroendocrine carcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement with response to alectinib, Internal Med, 2018, 57(5): 713-716.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
